298 related articles for article (PubMed ID: 8649650)
21. Beneficial effect of neutrophil elastase inhibitor on anti-Thy1.1 nephritis in rats.
Kumasaka R; Nakamura N; Fujita T; Murakami R; Shimada M; Osawa H; Yamabe H; Okumura K
Nephrology (Carlton); 2008 Feb; 13(1):27-32. PubMed ID: 18199098
[TBL] [Abstract][Full Text] [Related]
22. Single and multiple drug therapy in autologous immune complex nephritis in rats.
Kupor LR; Lowance DC; McPhaul JJ
J Lab Clin Med; 1976 Jan; 87(1):27-36. PubMed ID: 128575
[TBL] [Abstract][Full Text] [Related]
23. Sequential studies of glomerular crescent formation in rats with antiglomerular basement membrane-induced glomerulonephritis and the role of coagulation factors.
Silva FG; Hoyer JR; Pirani CL
Lab Invest; 1984 Oct; 51(4):404-15. PubMed ID: 6434880
[TBL] [Abstract][Full Text] [Related]
24. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
[TBL] [Abstract][Full Text] [Related]
25. Contribution of ED-1- and CD-8-positive cells to the development of crescentic-type anti-GBM nephritis in rats.
Hattori T; Nagamatsu T; Ito M; Suzuki Y
Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1228-39. PubMed ID: 7853754
[TBL] [Abstract][Full Text] [Related]
26. Reactive oxygen products in heterologous anti-glomerular basement membrane nephritis in rats.
Birtwistle RJ; Michael J; Howie AJ; Adu D
Br J Exp Pathol; 1989 Apr; 70(2):207-13. PubMed ID: 2786425
[TBL] [Abstract][Full Text] [Related]
27. Antifibrinolytics in cardiac surgery.
Dhir A
Ann Card Anaesth; 2013; 16(2):117-25. PubMed ID: 23545866
[TBL] [Abstract][Full Text] [Related]
28. [Studies on antinephritic effect of lipo PGE1 (1). Effect of lipo PGE1 on crescentic-type anti-GBM nephritis in rats].
Nagao T; Hattori T; Ito M; Suzuki Y
Nihon Jinzo Gakkai Shi; 1991 Mar; 33(3):247-56. PubMed ID: 2062010
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass.
Dorman BH; Stroud RE; Wyckoff MM; Zellner JL; Botta D; Leonardi AH; Ikonomidis JS; Spinale FG
J Cardiovasc Pharmacol; 2008 Apr; 51(4):418-23. PubMed ID: 18427286
[TBL] [Abstract][Full Text] [Related]
30. Clinical application of inhibitors of fibrinolysis.
Verstraete M
Drugs; 1985 Mar; 29(3):236-61. PubMed ID: 2580684
[TBL] [Abstract][Full Text] [Related]
31. Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost.
Ray MJ; O'Brien MF
Ann Thorac Surg; 2001 Mar; 71(3):838-43. PubMed ID: 11269462
[TBL] [Abstract][Full Text] [Related]
32. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis.
Iyoda M; Shibata T; Wada Y; Kuno Y; Shindo-Hirai Y; Matsumoto K; Akizawa T
Nephrol Dial Transplant; 2013 Mar; 28(3):576-84. PubMed ID: 23045430
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin.
Escribese MM; Conde E; Martín A; Sáenz-Morales D; Sancho D; Pérez de Lema G; Lucio-Cazaña J; Sánchez-Madrid F; García-Bermejo ML; Mampaso FM
BMC Nephrol; 2007 Jan; 8():3. PubMed ID: 17250768
[TBL] [Abstract][Full Text] [Related]
34. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid.
Greilich PE; Okada K; Latham P; Kumar RR; Jessen ME
Circulation; 2001 Sep; 104(12 Suppl 1):I265-9. PubMed ID: 11568067
[TBL] [Abstract][Full Text] [Related]
35. [Effects of reactive oxygen species scavenger and platelet activating factor receptor antagonist on accelerated nephrotoxic nephritis].
Kakuta S
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):115-24. PubMed ID: 8315875
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacological studies on experimental nephritic rats (13). The development and aggravation of nephritis due to the repeated administration of liquoid (author's transl)].
Ito M; Yokochi E; Kito T; Suzuki Y
Nihon Yakurigaku Zasshi; 1981 Apr; 77(4):419-25. PubMed ID: 6269971
[TBL] [Abstract][Full Text] [Related]
37. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.
Leh S; Vaagnes Ø; Margolin SB; Iversen BM; Forslund T
Nephrol Dial Transplant; 2005 Jan; 20(1):71-82. PubMed ID: 15561744
[TBL] [Abstract][Full Text] [Related]
38. Chemical and histochemical studies of glomerular sialoprotein in nephrotoxic nephritis in rats.
Chiu J; Drummond KN
Am J Pathol; 1972 Aug; 68(2):391-406. PubMed ID: 4114975
[TBL] [Abstract][Full Text] [Related]
39. [Production of reactive oxygen species and scavenger treatment in nephrotoxic nephritis].
Nakamura K
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):761-72. PubMed ID: 1479715
[TBL] [Abstract][Full Text] [Related]
40. Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis.
Takakura K; Mizukami K; Mitori H; Noto T; Tomura Y
Eur J Pharmacol; 2014 Aug; 737():106-16. PubMed ID: 24858365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
